You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The Phase I/II trial will assess the safety and efficacy of the CAR T cell therapy MB-102 for patients with three types of hematologic malignancies.
The program is in its third year monitoring individuals with these mutations to try to detect disease early, understand their risk, and develop preventive treatments.
Chi-Med subsidiary Hutchison Medipharma has kicked off the Phase I trial in China and has dosed its first patient with the investigational IDH inhibitor.
The aim of the study is to establish a tumor registry based on blood and bone marrow samples from cancer patients with linked outcomes data, which the firm can use for precision drug development.
CEO Troy Wilson unveiled the first data on tipifarnib demonstrating that biomarkers in the CXCL12 pathway identify which peripheral T-cell lymphoma patients respond best.
Cancer Moonshot-funded teams are profiling pre-cancers in an effort to establish targeted treatment, detection, and prevention methods that can be applied before cancers form.
A structural variant analysis based on genome sequences for almost 800 multiple myeloma cases suggests a IgL translocation present in nearly 10 percent of patients may inform survival.
The VA decided to bring this testing in house to streamline and standardize the process for doctors and gauge markers that are relevant to the veteran population.